VIP receptor research provides the mechanistic foundation for understanding how vasoactive intestinal peptide produces its diverse effects across multiple tissue systems. The two main VIP receptors, VPAC1 and VPAC2, are class B G protein coupled receptors that bind VIP and PACAP with comparable affinity and produce signaling through canonical Gs alpha pathways. As the receptor pharmacology component of the VIP research cluster, this article reviews the published literature on VPAC1 and VPAC2 structure, signaling pathways, tissue distribution, and the mechanism of action that underlies VIP research in animal models.
VIP Receptor Research: VPAC1 and VPAC2 Signaling in Research Models
VIP · Published April 8, 2026 · Updated May 18, 2026 · 8 min read
Quick Answer
VIP receptor research covers VPAC1 and VPAC2 structure, Gαs signaling pathways, and tissue distribution across CNS, gut, lung, and immune tissues. Studies examine receptor activation, downstream cAMP/PKA signaling, and the multi-receptor pharmacology underlying VIP research in cellular and rodent models. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Frequently Asked Questions
What is VIP in research contexts?
+
VIP (vasoactive intestinal peptide) is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily. It is studied in preclinical models for vasodilation, immune modulation, circadian rhythm regulation, and pulmonary smooth muscle research through VPAC1 and VPAC2 receptor signaling.
What distinguishes VPAC1 from VPAC2 receptors?
+
Both VPAC1 and VPAC2 are class B GPCRs binding VIP with high affinity. They differ in tissue distribution: VPAC1 is broadly expressed (gut, immune cells, lung, liver), while VPAC2 is enriched in SCN, smooth muscle, and select brain regions, defining tissue-specific signaling profiles.
How are VPAC receptors studied selectively?
+
Selective VPAC1 and VPAC2 agonists and antagonists allow dissection of receptor-specific effects. Genetic knockout models in mice (Vipr1, Vipr2) provide additional tools for parsing the contributions of each receptor to integrated VIP biology in research.
Is VIP approved for human use?
+
Glossary
Key terms used in this article.
- VPAC1
- Vasoactive intestinal peptide receptor 1, broadly distributed, mediating immune and gastrointestinal effects of VIP.
- VPAC2
- Vasoactive intestinal peptide receptor 2, enriched in the suprachiasmatic nucleus and lung, involved in circadian and pulmonary signaling.
- Suprachiasmatic Nucleus (SCN)
- The hypothalamic master circadian pacemaker, where VPAC2 signaling is essential for synchronizing rhythmic neuronal activity.
- Vasodilation
- Widening of blood vessels resulting from relaxation of vascular smooth muscle, often mediated by nitric oxide or VIP signaling.
- Neuropeptide
- A peptide produced and released by neurons that acts as a signaling molecule in the nervous system.
- Class B GPCR
- A subfamily of G protein-coupled receptors that includes the VPAC1, VPAC2, GLP-1, GIP, and GHRH receptors.
- Receptor Selectivity
- The pharmacological preference of a ligand for one receptor or pathway over others, minimizing off-target effects.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
